Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, …
Biotechnology
US, Newark [HQ]
Lobbying Analysis
Lobbying · US Senate · Influence
Rain Therapeutics Inc. has no lobbying expenses in our database.
History
Download| FY | Quarter | Expense For Lobby Disclosure | LDA Reference |
|---|---|---|---|
| No data |